Tech Company Financing Transactions
NightstaRx Funding Round
NightstaRx, operating out of London, secured $35 million from New Enterprise Associates and private investors.
Transaction Overview
Company Name
Announced On
11/10/2015
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series B
Investors
New Enterprise Associates (Lead Investor) (David Mott)
Proceeds Purpose
The funds will enable Nightstar to continue clinical development of its gene therapy for choroideremia and advance multiple retinal gene therapy programs into human trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
9-10 Midford Pl.
London, W1T 5BJ
UK
London, W1T 5BJ
UK
Phone
Website
Email Address
Overview
Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company's lead programme is a retinal gene therapy for Choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Fellows
Chief Financial Officer
Senthil Sundaram
Chief Medical Officer
Aniz Girach
Chief Scientific Officer
Gregory Robinson
Vice President
Julian Hanak
VP - Bus. Development
Tuyen Ong
VP - General Counsel
Bryan Yoon
VP - Regulatory Affairs
Mark Rosch
Browse more venture capital transactions:
Prev: 11/10/2015: Baby Bundle venture capital transaction
Next: 11/10/2015: Wave Systems venture capital transaction
Share this article
Where The Data Comes From
We report on tech company VC transactions. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs